Skip to main content

Advertisement

Table 1 2012 European LeukemiaNet prognostic-risk group based on cytogenetic and molecular profile

From: PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia

Prognostic-risk group Cytogenetic profile alone Cytogenetic profile and molecular abnormalities
Favorable t(8:21)(q22; q22) inv(16)(p13; 1q22) t(15;17)(q22; q12) t(8:21)(q22; q22) with no c-KIT mutation inv(16)(p13; 1q22) t(15;17)(q22; q12) Mutated NPM1 without FLT3-ITD (CN-AML) Mutated biallelic CEBPA (CN-AML)
Intermediate CN-AML t(9;11)(p22; q23) Cytogenetic abnormalities not included in the favorable or adverse prognostic risk groups t(8:21)(q22;q22) with mutated c-KIT CN-AML other than those included in the favorable or adverse prognostic group t(9;11)(p22; q23) Cytogenetic abnormalities not included in the favorable or adverse prognostic risk groups
Adverse inv(3)(q21q26.2) t(6;9)(p23; q34) 11q abnormalities other than t(9;11) −5 or del(5q) −7 Complex karyotype TP53 mutation, regardless of cytogenetic profile CN with FLT3-ITD CN with DNMT3A CN with KMT2A-PTD inv(3)(q21q26.2) t(6;9)(p23;q34) 11q abnormalities other than t(9;11) −5 or del(5q) −7 Complex karyotype
  1. CN-AML normal cytogenetics acute myeloid leukemia, ITD internal tandem duplications